Navjot Pabla

Image
Navjot Pabla

Navjot Pabla, PhD

Title
Assistant Professor
Unit / Department / Division
Pharmaceutics and Pharmacology
Address
402 Riffe Building
Email Address
Phone Number

Professional Interests

Professional Interests

Our laboratory is focused on identifying therapeutic targets for kidney diseases. Acute kidney injury and renal cell carcinoma are the two major areas of interest. Our recent work has identified several protein kinases and membrane transporters as therapeutic targets for renal disorders. We utilize high throughput screening assays and functional genomics to identify molecular targets for renal diseases, followed by validation in in vivo animal models. The overall goal of these studies is to identify new therapeutic strategies to treat acute kidney injury and renal cell carcinoma, diseases for which no effective therapies are currently available.

Education

  • 2009, PhD (Biomedical Sciences), Medical College of Georgia
  • 2003, M.Sc. (Biochemistry), Maharaja Sayajirao University of Baroda
  • 2001, B.Sc. (Biotechnology), Sardar Patel University

Journal Articles

  • Kim JY, Bai Y, Jayne LA, Cianciolo RE, Bajwa A, Pabla NS. Involvement of the CDKL5-SOX9 signaling axis in rhabdomyolysis-associated acute kidney injury. doi: 10.1152/ajprenal.00429.2020. AJP Renal Physiology. 2020; PubMed PMID: 33044867.
  • Kim JY, Bai Y, Jayne LA, Abdulkader F, Gandhi M, Perreau T, Parikh SV, Gardner DS, Davidson AJ, Sander V, Song MA, Bajwa A, Pabla NS. SOX9 promotes stress-responsive transcription of VGF nerve growth factor inducible gene in renal tubular epithelial cells. J Biol Chem. 2020. Epub 2020/09/06. doi: 10.1074/jbc.RA120.015110. PubMed PMID: 32887795.
  • Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS, Rojesh S, Raj R, Feng M, Chung S, Cianciolo RE, Christman JW, Campbell MJ, Gardner DS, Baker SD, Sparreboom A, Govindarajan R, Singh H, Chen T, Poi M, Susztak K, Cobb SR, Pabla NS. A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nature Communications. 2020;11(1):1924. Epub 2020/04/23. doi: 10.1038/s41467-020-15638-6. PubMed PMID: 32317630; PMCID: PMC7174303.
  • Kim JY, Jayne LA, Bai Y, Feng M, Clark MA, Chung S, J WC, Cianciolo RE, Pabla NS. Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms. Biochem Pharmacol. 2020;177:113939. Epub 2020/04/02. doi: 10.1016/j.bcp.2020.113939. PubMed PMID: 32229099.